Investigation of Efficacy and Outcome of a New Medical Device for Treatment of Migraine
Primary Purpose
Migraine
Status
Terminated
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
In-house prototype invented by Jan-Erik Juto
In-house prototype invented by Jan-Erik Juto
Sponsored by
About this trial
This is an interventional treatment trial for Migraine
Eligibility Criteria
Inclusion Criteria:
- Female or male subjects, in otherwise good health, 20 to 55 years of age
- Subjects who meet the ICHD-2 (2nd Edition of The International Headache Classification) criteria for migraine headache
- Subjects with a minimum of 1 migraine attack per month
- Attack duration of 4 to 72 hours
- Normal attack intensity of at least 4 on a 0-10 VAS-scale
Exclusion Criteria:
- Completed heart surgery
- Cardiovascular diseases
- Vascular damages on neck vessels
- Diseases other than migraine of the CNS
- Severe disease of vital body organs
- Severe psychiatric disorders
- More than 6 migraine attacks per month
Sites / Locations
- Karolinska University Hospital, Huddinge
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Migraine medical device
Inactive migraine medical device
Arm Description
Treatment with an active nasal probe
Treatment with an inactive nasal probe.
Outcomes
Primary Outcome Measures
Change from baseline in pain intensity according to VAS-scales (0-10)
Documentation of pain intensity prior to treatment initiation (baseline value), every 5 minutes during treatment and post treatment.
Secondary Outcome Measures
RR (Heart rate)-interval
ECG will be obtained during treatment
Change from baseline in sympathetic nervous system activity
Plethysmographic measurements will be obtained during treatment (finger clamp on finger).
Blood pressure
Will be obtained prior to treatment initiation and post treatment
Change from baseline in attack frequency based on completed patient diaries
Change from baseline in attack intensity based on completed patient diaries
Change from baseline in attack duration based on completed patient diaries
Change from baseline in medicine consumption based on completed patient diaries
Full Information
NCT ID
NCT01488110
First Posted
December 2, 2011
Last Updated
June 17, 2013
Sponsor
Karolinska University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01488110
Brief Title
Investigation of Efficacy and Outcome of a New Medical Device for Treatment of Migraine
Official Title
Undersökning av ny Behandlingsmetod Vid migränanfall (Evaluation of a New Treatment for Migraine Attacks)
Study Type
Interventional
2. Study Status
Record Verification Date
June 2013
Overall Recruitment Status
Terminated
Why Stopped
Too slow recruitment rate. The study has been terminated and will be re-started with an improved and more suitable study design.
Study Start Date
January 2012 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Karolinska University Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the efficacy of a novel therapy for treatment of migraine, pain reduction and relief of associated symptoms during ongoing migraine attacks, and presence of a preventive effect two months post treatment. Another purpose is to investigate if and how this treatment affects manifestations of the autonomic nervous system activity.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Migraine
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Migraine medical device
Arm Type
Experimental
Arm Description
Treatment with an active nasal probe
Arm Title
Inactive migraine medical device
Arm Type
Placebo Comparator
Arm Description
Treatment with an inactive nasal probe.
Intervention Type
Device
Intervention Name(s)
In-house prototype invented by Jan-Erik Juto
Intervention Description
30 minutes treatment with an active nasal probe.
Intervention Type
Device
Intervention Name(s)
In-house prototype invented by Jan-Erik Juto
Intervention Description
30 minutes treatment with an inactive nasal probe.
Primary Outcome Measure Information:
Title
Change from baseline in pain intensity according to VAS-scales (0-10)
Description
Documentation of pain intensity prior to treatment initiation (baseline value), every 5 minutes during treatment and post treatment.
Time Frame
Estimation 40 minutes
Secondary Outcome Measure Information:
Title
RR (Heart rate)-interval
Description
ECG will be obtained during treatment
Time Frame
Estimation 40 minutes
Title
Change from baseline in sympathetic nervous system activity
Description
Plethysmographic measurements will be obtained during treatment (finger clamp on finger).
Time Frame
Estimation 40 minutes
Title
Blood pressure
Description
Will be obtained prior to treatment initiation and post treatment
Time Frame
Estimation 40 minutes
Title
Change from baseline in attack frequency based on completed patient diaries
Time Frame
3 to 4 months
Title
Change from baseline in attack intensity based on completed patient diaries
Time Frame
3 to 4 months
Title
Change from baseline in attack duration based on completed patient diaries
Time Frame
3 to 4 months
Title
Change from baseline in medicine consumption based on completed patient diaries
Time Frame
3 to 4 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Female or male subjects, in otherwise good health, 20 to 55 years of age
Subjects who meet the ICHD-2 (2nd Edition of The International Headache Classification) criteria for migraine headache
Subjects with a minimum of 1 migraine attack per month
Attack duration of 4 to 72 hours
Normal attack intensity of at least 4 on a 0-10 VAS-scale
Exclusion Criteria:
Completed heart surgery
Cardiovascular diseases
Vascular damages on neck vessels
Diseases other than migraine of the CNS
Severe disease of vital body organs
Severe psychiatric disorders
More than 6 migraine attacks per month
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Juto
Organizational Affiliation
Karolinska University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Karolinska University Hospital, Huddinge
City
Stockholm
ZIP/Postal Code
14186
Country
Sweden
12. IPD Sharing Statement
Learn more about this trial
Investigation of Efficacy and Outcome of a New Medical Device for Treatment of Migraine
We'll reach out to this number within 24 hrs